Effects of circadian clock gene Period2 on Warburg effect and metastasis in hepatocellular carcinoma cells

doi:10.12092/j.issn.1009-2501.2019.10.008

Abstract

Abstract:

AIM: To study the effects of circadian clock gene Period2 on Warburg effect and metastasis in hepatocellular carcinoma cells. METHODS: Real-time fluorescence quantitative PCR (RT-QPCR) was used to detect the expression of Period2 in tissues and 4 hepatocellular carcinoma cells,up-regulated the expression of Period2 in hepatocellular carcinoma cell line MHCC97L.silenced the expression of Period2 in hepatocellular carcinoma cell line HepG2.The glucose uptake level,lactic acid level，cell oxygen consumption level，cell viability，migration,and cell invasion were detected.Western-Blot was used to detect the expression of the key metabolic enzymes.RESULTS:The expression level of Period2 in MHCC97L was low,while HepG2 level was high.After Period2 silencing, the relative glucose uptake and lactate production of HepG2 cells were down-regulated compared with control group, and the oxygen consumption of HepG2 cells was increased compared with control,and the cell viability, migration and invasion ability were decreased.The expression level of key enzymes of glycometabolism was down-regulated.After overexpression of Period2,the glucose uptake level of MHCC97L cells was increased,the lactate production level was increased,the oxygen consumption was decreased compared with control, and the cell viability, migration and invasiveness were increased.The expression level of key enzymes of glucose metabolism was up-regulated.CONCLUSION: The clock gene Period2 is highly expressed in HCC, and its role is related to the promotion of Warburg effect and metastasis and invasion of HCC cells.

Key words: clock gene, cancer, Hepatocyte, Warburg effect, metastasis, invasion

CLC Number:

ZHAO Qiaosu，YE Hua，SUN Qinxue. Effects of circadian clock gene Period2 on Warburg effect and metastasis in hepatocellular carcinoma cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1134-1141.

References

［1］Benna C,Helfrich-Frster C,Rajendran S,et al.Genetic variation of clock genes and cancer risk:a field synopsis and meta-analysis［J］.Oncotarget,2017,8(14):23978-23995.
［2］Dudek M,Gossan N,Yang N,et al.The chondrocyte clock gene Bmal1 controls cartilage homeostasis and integrity［J］.J Clin Invest,2016,126(1):365-372.
［3］Miki T,Matsumoto T,Zhao Z,et al.p53 regulates Period2 expression and the circadian clock［J］.Nat Commun，2013,4(9):2444.
［4］Gotoh T,Vilacaballer M,Santos CS,et al.The circadian factor Period 2 modulates p53 stability and transcriptional activity in unstressed cells［J］.Mol Biol Cell，2014,25(19):3081-3093.
［5］Verneaux V,Jouvenot M,Compagnone P,et al.Expression of c-fos and c-myc genes in uterus and nonreproductive organs during the implantation period in the rat.［J］.Biochem Cell Biol，1992, 70(2):142-148.
［6］Li X,Yu X,Dong D,et al.The altered glucose metabolism in tumor and a tumor acidic microenvironment associated with extracellular matrix metalloproteinase inducer and monocarboxylate transporters［J］.Oncotarget,2016,7(17):23141-23155.
［7］Tambe Y,Hasebe M,Kim CJ,et al.The drs tumor suppressor regulates glucose metabolism via lactate dehydrogenase-B［J］.Mol Carcinog，2016,55(1):52-63.
［8］Bosch F X,Ribes J,Díaz M,et al.Primary liver cancer:Worldwide incidence and trends［J］.Gastroenterology,2004,127(5):S5-S16.
［9］Savic LJ,Chapiro J,Duwe G,et al.Targeting glucose metabolism in cancer:new class of agents for loco-regional and systemic therapy of liver cancer and beyond［J］?Hepat Oncol,2016,3(1):19-28.
［10］Hsu PP,Sabatini DM.Cancer cell metabolism: Warburg and beyond［J］.Cell,2008,134(5):703-707.
［11］Wei H,Guo L,Li L,et al.Mechanism of Warburg effect and its effect on tumor metastasis［J］.Zhong guo Fei Ai Za Zhi，2015，18(3):179-183.
［12］Hardie DG,Alessi DR.LKB1 and AMPK and the cancer-metabolism link-ten years after［J］.Bmc Biology,2013,11(1):36.
［13］Tanaka T,Ikegami Y,Nakazawa H，et al.Low-dose farnesyltransferase inhibitor suppresses hif-1α and snail expression in triple-negative breast cancer MDA-MB-231 cells in vitro［J］.J Cell Physiol，2016,232(1):192-201.
［14］王瑾，杨毅，郭丽，等.普罗布考通过调节肝癌细胞HepG2代谢重编程逆转Warburg效应抑制其转移和侵袭的机制研究［J］.中国临床药理学与治疗学,2018,23(6):601-607.

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[3]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[4]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[5]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[6]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[7]	CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing. Clinical application and research progress of antibody drugs conjugation in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909.
[8]	LI Mengxi, ZHANG Kejing, XIA Fan. Research progress in vaccine for breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 918-925.
[9]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[10]	ZHANG Jinghui, WEI Haoliang, WANG Li, LI Jingkai, ZHANG Baolai, YANG Xiaolai. Effects of AMI-1 on the activity of pancreatic cancer cells in vitro by down-regulating PRMT5 expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 601-608.
[11]	FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
[12]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[13]	FENG Zhuangzhuang, SONG Ruiping, DOU Pengcheng, CHEN Xinyi, ZUO Jiaojiao, SHU Jin. Effect of Zhiwei Fuwei Pills on autophagy in gastric antrum tissue of rats with precancerous lesions of gastric cancer based on mTOR/Beclin1/LC3 signaling axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 361-370.
[14]	SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
[15]	WEI Zhenzhen, SUI Hua, JIANG Yulang, SUN Mingyu, YAN Huaru, WANG Ziyuan. Research on the molecular mechanism of Zuo Jin Wan combined with cetuximab inducing ferroptosis in KRAS mutant colorectal cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 130-137.